Table S3 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
Key Points
Key points are not available for this paper at this time.
Abstract
Table S3. Demographic and clinical characteristics of the patients
KI fragen
Like
Bookmark
Share
KI fragen
Like
Bookmark
Share
Table S3 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation | Synapse